SG Americas Securities LLC Boosts Stock Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

SG Americas Securities LLC grew its holdings in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 25.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,623 shares of the company’s stock after buying an additional 6,206 shares during the quarter. SG Americas Securities LLC’s holdings in Poseida Therapeutics were worth $294,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in PSTX. Marshall Wace LLP acquired a new stake in Poseida Therapeutics in the second quarter valued at $31,000. Virtu Financial LLC acquired a new stake in shares of Poseida Therapeutics in the 3rd quarter valued at about $37,000. Brooklyn Investment Group bought a new position in shares of Poseida Therapeutics during the fourth quarter worth about $40,000. Intech Investment Management LLC bought a new position in shares of Poseida Therapeutics during the third quarter worth about $46,000. Finally, Mackenzie Financial Corp acquired a new position in Poseida Therapeutics in the second quarter worth about $51,000. Institutional investors and hedge funds own 46.87% of the company’s stock.

Poseida Therapeutics Stock Performance

NASDAQ:PSTX opened at $9.50 on Thursday. The firm has a market capitalization of $928.85 million, a P/E ratio of -15.08 and a beta of 1.63. The business has a 50 day simple moving average of $9.47 and a 200 day simple moving average of $5.26. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 3.20. Poseida Therapeutics, Inc. has a 12-month low of $1.87 and a 12-month high of $9.67.

Poseida Therapeutics (NASDAQ:PSTX) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.21 EPS for the quarter, topping the consensus estimate of ($0.42) by $0.63. The business had revenue of $71.75 million during the quarter, compared to analyst estimates of $15.00 million. Poseida Therapeutics had a negative net margin of 40.28% and a negative return on equity of 72.26%. Equities research analysts predict that Poseida Therapeutics, Inc. will post -1.02 EPS for the current year.

Wall Street Analysts Forecast Growth

PSTX has been the topic of several research reports. Cantor Fitzgerald cut Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 26th. BTIG Research reissued a “neutral” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. William Blair reaffirmed a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Piper Sandler cut shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 target price on the stock. in a report on Monday, December 2nd. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 price target (down from $20.00) on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Five analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.50.

Insiders Place Their Bets

In other news, Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.46, for a total transaction of $283,800.00. Following the completion of the transaction, the chairman now directly owns 651,291 shares in the company, valued at approximately $6,161,212.86. The trade was a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.90% of the stock is owned by insiders.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.